Generics Bulletin is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Generics Firms Race To Withdraw ANDAs

Executive Summary

Industry consolidation may be a reason ANDA withdrawals have increased during GDUFA II.


Related Content

Senate Drug Pricing Legislation Clears Committee With Generic Exclusivity “Parking” Provision Unchanged
US FDA First-Cycle ANDA Approvals Not Rising Along With Full Clearances
Generic Industry Market Forces May Impact GDUFA III Talks
US FDA's Generics Program Reaches 'Steady State' Milestone
How US FDA's Assumptions Impacted Generic Program Fees
Inside The ANDA Parking Lot





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts